The Italian Medicines Agency (AIFA) has published an update on the access criteria for the AIFA 5% Fund, established by Decree-Law no. 269/2003 and converted by Law no. 326/2003. The Fund, financed by contributions from pharmaceutical companies equal to 5% of annual promotional expenses directed at healthcare professionals, is intended to support the use of orphan drugs for the treatment of rare diseases and drugs that represent a hope of cure for serious pathologies, including those awaiting marketing authorization.
The AIFA 5% Fund represents a fundamental tool for supporting research and access to innovative treatments, strengthening the Agency’s role in ensuring equity, sustainability, and safety within pharmaceutical assistance.
For more information and to consult the complete document on access criteria: criteri_accesso_fondo_AIFA_20.06.203
